Cargando…
Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is av...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507103/ https://www.ncbi.nlm.nih.gov/pubmed/31118734 http://dx.doi.org/10.2147/CEG.S150908 |
_version_ | 1783416960063635456 |
---|---|
author | Tran, Vivy Shammas, Rania M Sauk, Jenny S Padua, David |
author_facet | Tran, Vivy Shammas, Rania M Sauk, Jenny S Padua, David |
author_sort | Tran, Vivy |
collection | PubMed |
description | The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is available through several small molecule inhibitors, including tofacitinib. Tofacitinib is an orally administered pan-JAK inhibitor that was first approved by the Food and Drug Administration (FDA) for use in rheumatologic disorders such as rheumatoid arthritis and psoriatic arthritis. The FDA approved its use in moderate-to-severe active ulcerative colitis in 2018. The aim of this review will be to discuss the role of tofacitinib in ulcerative colitis. We will discuss the role of JAK-STAT signaling, clinical data available for tofacitinib, and the safety profile for this therapy. Tofacitinib’s place in the UC management algorithm is currently being debated. This effective oral therapy is poised to be a mainstay of UC therapeutics. This review will highlight the key clinical features and detail the UC experience to date. |
format | Online Article Text |
id | pubmed-6507103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65071032019-05-22 Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy Tran, Vivy Shammas, Rania M Sauk, Jenny S Padua, David Clin Exp Gastroenterol Review The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is available through several small molecule inhibitors, including tofacitinib. Tofacitinib is an orally administered pan-JAK inhibitor that was first approved by the Food and Drug Administration (FDA) for use in rheumatologic disorders such as rheumatoid arthritis and psoriatic arthritis. The FDA approved its use in moderate-to-severe active ulcerative colitis in 2018. The aim of this review will be to discuss the role of tofacitinib in ulcerative colitis. We will discuss the role of JAK-STAT signaling, clinical data available for tofacitinib, and the safety profile for this therapy. Tofacitinib’s place in the UC management algorithm is currently being debated. This effective oral therapy is poised to be a mainstay of UC therapeutics. This review will highlight the key clinical features and detail the UC experience to date. Dove 2019-05-02 /pmc/articles/PMC6507103/ /pubmed/31118734 http://dx.doi.org/10.2147/CEG.S150908 Text en © 2019 Tran et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Tran, Vivy Shammas, Rania M Sauk, Jenny S Padua, David Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
title | Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
title_full | Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
title_fullStr | Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
title_full_unstemmed | Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
title_short | Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
title_sort | evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507103/ https://www.ncbi.nlm.nih.gov/pubmed/31118734 http://dx.doi.org/10.2147/CEG.S150908 |
work_keys_str_mv | AT tranvivy evaluatingtofacitinibcitrateinthetreatmentofmoderatetosevereactiveulcerativecolitisdesigndevelopmentandpositioningoftherapy AT shammasraniam evaluatingtofacitinibcitrateinthetreatmentofmoderatetosevereactiveulcerativecolitisdesigndevelopmentandpositioningoftherapy AT saukjennys evaluatingtofacitinibcitrateinthetreatmentofmoderatetosevereactiveulcerativecolitisdesigndevelopmentandpositioningoftherapy AT paduadavid evaluatingtofacitinibcitrateinthetreatmentofmoderatetosevereactiveulcerativecolitisdesigndevelopmentandpositioningoftherapy |